Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer

Oncotarget

Volumn 7, Issue 22, 2016, Pages 32210-32220

  Liu, Chengfei ^a   Armstrong, Cameron ^a   Zhu, Yezi ^a   Lou, Wei ^a   Gao, Allen C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abiraterone; Androgen receptor variant; Niclosamide; Prostate cancer; Resistance

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR VARIANT 7; ENZALUTAMIDE; NICLOSAMIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; PHENYLTHIOHYDANTOIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; THERAPY RESISTANCE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETIC VARIATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; ANDROSTENES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENETIC VARIATION; HUMANS; MALE; MICE, SCID; NICLOSAMIDE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RNA INTERFERENCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84973572847     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8493     Document Type: Article

References (44)

1. Attard G, Reid AH, Olmos D and de Bono JS. Antitumor activity with CYP17 blockade indicates that castrationresistant prostate cancer frequently remains hormone driven. Cancer research. 2009; 69:4937-4940.
2. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. Journal of clinical oncology. 2009; 27:3742-3748.
3. Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ and Sharifi N. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015; 523: 347-351.
4. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, et al. Abiraterone and increased survival in metastatic prostate cancer. The New England journal of medicine. 2011; 364:1995-2005.
5. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England journal of medicine. 2013; 368:138-148.
6. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapynaive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2015; 16:152-160.
7. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England journal of medicine. 2012; 367:1187-1197.
8. Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S and de Bono JS. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. European journal of cancer. 2014; 50:78-84.
9. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS and Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of oncology. 2013; 24:1807-1812.
10. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL and Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of oncology. 2013; 24:1802-1807.
11. Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E and Cronauer MV. Enzalutamide in castrationresistant prostate cancer patients progressing after docetaxel and abiraterone. European urology. 2014; 65:30-36.
12. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M and Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scandinavian journal of urology. 2013; 48:268-275.
13. van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R and van Weerden WM. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. European journal of cancer. 2013; 49:3821-3830.
14. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS and Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical cancer research. 2011; 17:5913-5925.
15. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S and Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer research. 2011; 71:6503-6513.
16. Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C and Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical cancer research. 2014; 20:1590-1600.
17. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical cancer research. 2015; 21:2315-2324.
18. Chen EJ, Sowalsky AG, Gao S, Cai C, Voznesensky O, Schaefer R, Loda M, True LD, Ye H, Troncoso P, Lis RL, Kantoff PW, Montgomery RB, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clinical cancer research. 2015; 21:1273-1280.
19. Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH and Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer research. 2011; 71:2108-2117.
20. Dehm SM and Tindall DJ. Alternatively spliced androgen receptor variants. Endocrine-related cancer. 2011; 18:R183-196.
21. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS and Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer research. 2009; 69:16-22.
22. Zhang Z, Zhou N, Huang J, Ho TT, Zhu Z, Qiu Z, Zhou X, Bai C, Wu F, Xu M and Mo YY. Regulation of androgen receptor splice variant AR3 by PCGEM1. Oncotarget. 2016; doi: 10.18632/oncotarget.7139.
23. Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP and Gao AC. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Molecular cancer therapeutics. 2013; 12:1629-1637.
24. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA and Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer research. 2013; 73:483-489.
25. Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K and Schrader AJ. Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. 2015; doi: 10.18632/oncotarget.3925.
26. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014; 371:1028-1038.
27. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP and Gao AC. Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2014; 20:3198-3210.
28. Liu C, Lou W, Armstrong C, Zhu Y, Evans CP and Gao AC. Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. The Prostate. 2015; 75:1341-1353.
29. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP and Gao AC. Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer research. 2015; 75:1413-1422.
30. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C and Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. European urology. 2015; 67:23-29.
31. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 2012; 367:1187-1197.
32. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer research. 2009; 69:2305-2313.
33. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR and Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer research. 2012; 72:3457-3462.
34. Hayes WJ, Jr., E.R. Laws, Jr. Handbook of Pesticide Toxicology Classes of Pesticides New York, NY: Academic Press, Inc. 1991; 3:1496-1499.
35. Andrews P, Thyssen J and Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacology & therapeutics. 1982; 19:245-295.
36. Li YH, Li PK, Roberts MJ, Arend RC, Samant RS and Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 2014; 349:8-14.
37. Anon. Drugs for parasitic infections. The Medical letter on drugs and therapeutics. 1988; 30:15-24.
38. Ronald NC and Wagner JE. Treatment of Hymenolepis nana in hamsters with Yomesan (niclosamide). Laboratory animal science. 1975; 25:219-220.
39. Most H, Yoeli M, Hammond J and Scheinesson GP. Yomesan (niclosamide) therapy of Hymenolepis nana infections. The American journal of tropical medicine and hygiene. 1971; 20:206-208.
40. Jones WE. Niclosamide as a treatment for Hymenolepis diminuta and Dipylidium caninum infection in man. The American journal of tropical medicine and hygiene. 1979; 28:300-302.
41. Al-Hadiya BM. Niclosamide: comprehensive profile. Profiles of drug substances, excipients, and related methodology. 2005; 32:67-96.
42. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR and Luo J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer research. 2013; 72:3457-3462.
43. Liu C, Zhu Y, Lou W, Cui Y, Evans CP and Gao AC. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. The Prostate. 2014; 74:201-209.
44. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW and Gao AC. Functional p53 determines docetaxel sensitivity in prostate cancer cells. The Prostate. 2013; 73:418-427.